Background. Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)-positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality.
Liver diseases are among the most frequent causes of non-AIDS-related deaths in human immunodeficiency virus (HIV)-positive persons [1] [2] [3] [4] . Most deaths result from hepatitis C (HCV) or hepatitis B virus (HBV) coinfections or alcohol use; little is known about other causes [5] . Results of 2 prospective observational cohorts suggest that prolonged exposure to antiretroviral therapy (ART) may increase the risk for fatal liver failure. The Data Collection on Adverse Events of Anti-HIV Drug (D:A:D) cohort, which includes many HCV-coinfected persons, found an increased rate of liver-related deaths per year of ART in multivariable analyses that were also adjusted for the latest CD4 cell counts [1] . The EuroSIDA observational cohort showed similar results [6] .
The role of ART in liver-related mortality in patients without chronic viral hepatitis is less well defined. In the Swiss HIV Cohort Study (SHCS), elevated alanin aminotransferase (ALT; reported as adverse events to antiretrovirals), was associated with a higher mortality, independent of chronic hepatitis virus coinfections [7] . In contrast, mortality was not increased in participants with chronic ALT elevation and without viral hepatitis in another SHCS analysis; however, the observation period was shorter and the patient number smaller [8] . Recently, new hepatic syndromes related to ART have emerged in HIV-infected persons. Noncirrhotic portal hypertension, a potentially lifethreatening liver disease, has been linked to didanosine use [9, 10] . In addition, steatosis and steatohepatitis are common in HIV-positive persons with and without chronic viral hepatitis [11, 12] and are associated with advanced liver fibrosis and cirrhosis [13] ; ART as a risk factor has been discussed.
The aims of this study were to (1) assess liver-related mortality in HIV-positive persons without chronic viral hepatitis in the D:A:D cohort and (2) provide comprehensive clinical details of these events. The role of ART in death was of particular interest.
METHODS

Study Design
The D:A:D study, which was founded in 1999, is a prospective observational study of 11 previously established cohorts, as described previously [14] . Currently, 49 737 HIV-positive individuals (33 308 from the original 2 recruitments with 16 429 added to the cohort from 2009) are followed at 212 clinics in Europe, the United States, and Australia. The study's primary endpoint is myocardial infarction, with other events (including death) as secondary endpoints.
Data Collection
All participants were under active follow-up in their individual cohorts at the time of enrollment in the D:A:D study. At enrollment and at least every 8 months thereafter, standardized data forms, which are used to collect information on sociodemographic, clinical, laboratory, and treatment information, are completed. Data on HBV and HCV antibody status and hepatitis viral load assessments, if available, have been collected since January 2004. Previously collected HBV or HCV results by the participating cohorts were included. Information on cause of death has been prospectively collected using the Cause of Death (CoDe) in HIV protocol, which is specifically designed for classifying causes of death in HIV-positive persons [15] .
For the present analysis, deaths were classified as liver related if the underlying cause was recorded as liver failure, regardless of etiology. Other categories include AIDS, cardiovascular disease (CVD), non-AIDS malignancy (excluding AIDSdefining and hepatitis virus-associated malignancies), and other/unknown.
In all persons with liver-related death and negative HCV or HBV status, local investigators of participating institutions retrospectively reviewed the clinical charts using a structured questionnaire. This chart review ascertained that inclusion criteria were met and provided additional information on the cause of liver-related death (including severe alcohol use, nonalcoholic fatty liver disease, medical treatment, noncirrhotic portal hypertension, and other disorders), liver-related symptoms, laboratory and histology results, and interventions, including liver transplantation. In unclear circumstances of liver-related death, a brief narrative was given.
Definitions
HCV infection was defined as present in persons who were seropositive for HCV or who had test results positive for HCV RNA. HBV infection was defined as present in persons who were positive for hepatitis B surface antigen, hepatitis B e antigen, or hepatitis B core antibodies or who had detectable HBV DNA during the study period. Thus, patients with chronic and previous HCV infections and chronic, active, and previous HBV infections were excluded. Patients with unknown HBV or HCV status were also excluded. Severe alcohol use was defined according to the WHO definition as alcohol consumption in female >40 g/d and in male >60 g/d.
Statistical Analyses
All D:A:D study participants with negative HCV and HBV status were included. Participants were followed from the date of entry into the D:A:D study until the date of death, the date of loss to follow-up (6 months after the patient's last clinic visit), or the end of study follow-up (1 February 2010) , whichever occurred first. The incidence of liver-related deaths was defined as the number of such deaths divided by the total person-years of follow-up. HCV-or HBV-negative participants with liver-related death were compared with participants without chronic viral hepatitis who died from causes that were not liver related using data at baseline and data from the last clinic visit before death. P values were calculated using Fisher exact tests and Mann-Whitney U tests, as appropriate. Due to the small number of endpoints, multivariable analyses were not feasible. Analyses were performed using SAS version 9.1.
RESULTS
Baseline Characteristics
Of 49 737 participants followed between 1 December 1999 and 1 February 2010, 19 618 (40%) were HCV or HBV positive at baseline or during follow-up and 2506 (5%) had unknown HCV or HBV status. A total of 4703 (9%) participants were excluded because they belonged to cohorts that did not provide the requested information for this study. Thus, 22 910 (46%) HCV-and HBV-negative participants who were followed for 114 478 patient-years were included in these analyses ( Figure 1 ). Over the years, the percentage of patients with documentation gaps of more than 1 year remained low and varied between 3% and 6%. The baseline characteristics of the study participants are shown in Table 1 .
A total of 1059 (4.6%) of the patients died; 12 (0.05%) deaths were liver related. Thus, the incidence of liver-related deaths in persons not coinfected with HCV or HBV was 0.10/ 1000 person-years (95% confidence interval [CI] , .05, .18).
Description of Patients Who Died From Liver Disease
Clinical data are summarized in Table 2 . Five participants died due to ART toxicity. Of these, 2 patients experienced acute liver failure with lactic acidosis on regimens that included didanosine and stavudine, with 1 patient also receiving metformin. A third patient developed fatal liver failure because of a hypersensitivity reaction to nevirapine. Two patients died of noncirrhotic portal hypertension; both had been exposed to didanosine. The rate of ART-related death in treatment-experienced individuals was 0.04 (95% CI, 0.01, 0.10), with 5 events over 1000 person-years. Seven liver-related deaths were due to severe alcohol use, including 1 patient with an additional diagnosis of hemochromatosis.
Histopathological findings (2 biopsies and 1 autopsy) confirmed the clinical diagnosis of alcoholic liver disease and noncirrhotic portal hypertension. (Signs of alcoholic liver disease were found in 1 biopsy and in the autopsy of 2 patients with alcoholic liver disease, and 1 biopsy of a patient with noncirrhotic portal hypertension showed histopathological findings consistent with noncirrhotic portal hypertension) [10, 16] . No patient was treated with transjugular intrahepatic portal systemic shunting and none received a liver transplant. Participants who died from all causes compared with patients who remained alive were more often male and were older. Their first HIV diagnosis was earlier, their nadir and baseline CD4 cell counts were lower, maximum HIV-1 RNA levels were higher, and a history of previous clinical AIDS was more frequent (data not shown (Table 3) .
DISCUSSION
In this large prospective cohort of 22 910 HIV-positive participants without hepatitis coinfection who were followed for 114 478 patient-years, the incidence of liver-related deaths was very low at 0.10/1000 patient-years. Among the 12 persons who died from liver-related causes, 7 died because of alcohol use and 5 most probably as a consequence of ART-related hepatotoxicity.
In the large population-based National Health and Nutrition Examination Survey (NHANES) III study in the United States, liver-related mortality in adults who were HCV antibody negative was 0.16 (95% CI, .10-.25) per 1000 personyears; this is very similar to our finding of 0.10 (0.05-0.18) per 1000 person-years among HIV-positive individuals without HCV or HBV. However, in the NHANES III study, mortality of persons with chronic HCV infection was 4.4 (1.5-12.9) per 1000 person-years [17] .
In HIV-positive persons without HCV or HBV coinfection, limited data are available on liver-related mortality. In the French Mortavic study, 48 of 287 deaths (17%) in HIV-positive individuals in 2005 were related to end-stage liver disease, of which 94% of deaths were attributable to chronic viral hepatitis. Severe alcohol use was reported in nearly half of the patients, and only 3 of 48 persons were HCV/HBV-negative [3] . In a recent collaborative analysis of 13 HIV cohorts, 113 of 1876 deaths (7%) were related to liver diseases. In 50 patients (44%), hepatitis viruses were not the cause of liver-related death. However, information on the proportion of patients with positive or unknown HCV/HBV serostatus was missing [18] . A previous analysis of the D:A:D study group found 341 of 2482 deaths (14%) to be liver related; 56 patients (2.3%) with liver failure had no documentation of chronic viral hepatitis [4] . However, our current reinvestigation showed that chronic hepatitis virus infection was frequent in the group without HCV or HBV documentation.
We found that noncirrhotic portal hypertension was the cause of only 2 liver-related deaths. Several case series and case reports on the disease have been published recently [10, [10] . Fortunately, current data indicate that it is indeed a rare disease with a lower mortality than previously suspected. We found 2 liver-related deaths attributable to severe hyperlactataemia. In both cases, regimens included stavudine and didanosine. Exposure to nucleoside reverse transcriptase inhibitors, particularly to the dideoxynucleosides (didanosine, stavudine, and zalcitabine), is associated with the inhibition of mitochondrial DNA γ-polymerase, leading to severe hyperlactatemia. Lactic acidosis is rarely observed; however, the mortality rate is high [23, 24] , which is the reason that these drugs are no longer recommended. Nonnucleoside reverse transcriptase inhibitors, especially nevirapine, are associated with an increased risk of acute hepatotoxicity, typically due to hypersensitivity reactions. In line with our study findings, such adverse events are rare [25, 26] . We expected that liver-related deaths in persons not coinfected with hepatitis viruses were frequently due to severe alcohol consumption. Among HIV-positive persons, the reported prevalence of severe alcohol use ranges from 2.8% to 35%, depending on the observed population [27] [28] [29] [30] . However, we found a low rate of death to be due to alcoholic liver disease, which is probably explained by the exclusion of many at-risk patients such as injection-drug users. Those in this patient group, who are at risk for multiple substance-dependence syndromes including alcohol [30] , were almost completely excluded from analyses because of chronic viral hepatitis.
In agreement with other investigations, older age, male gender, lower CD4 cell counts, high HIV-1 viral load, and previous clinical AIDS were associated with death from all causes [18, 31] . We found that patients with liver-related death had been exposed to ART for a longer period of time and were known to be HIV-infected for a longer period of time. Both of these conditions might indicate a longer exposure to older and more hepatotoxic antiretrovirals. This is also true for patients with alcoholic liver disease, in whom the cause of death might have been multifactorial. However, this remains speculative because of the low number of endpoints.
The strength of this study is its large size and the long-term prospective observation. Additionally, the endpoint, that is, liver-related cause of death, was prospectively collected and centrally adjudicated using the CoDe system. Limitations are that multivariable analyses to identify associated risk factors were not possible because of the rare occurrence of endpoints under investigation; information on severe alcohol use was available only in case patients; and liver-related deaths were retrospectively reevaluated. We cannot rule out some underreporting of liver-related deaths. First, liver-related deaths might be difficult to capture because of multiple potential contributing factors (eg, sepsis or renal dysfunction). Central adjudication by several experienced clinicians, however, should have minimized such misclassifications. Second, some patients may have experienced liver-related death after being lost to follow-up, a scenario that might be more common in patients with alcoholic liver disease. However, because patients totally lost from HIV care are unlikely to be on ART, these missed events are unlikely to contribute to rates of ART-related liver mortality. Furthermore, because follow-up on such patients is right-censored on the date of loss to follow-up, our rate estimates should not be substantially biased by the exclusion of these events. Finally, given the very small number of events that limited a multivariable analysis of predictors of these liver-related deaths, it was not possible to perform a formal competing risks analysis to account for individuals who died of other causes prior to the clinical manifestation of liver disease.
In conclusion, this is the first large study to assess liverrelated deaths in HCV or HBV seronegative patients. The incidence of liver-related deaths unrelated to chronic viral hepatitis, in particular life-threatening hepatotoxic side effects due to antiretrovirals, was very low and comparable to that of the general HCV-negative population in the United States. This is good news in times when HIV infection has evolved into a chronic disease, lifelong ART remains a necessity, earlier therapy for all HIV-positive persons is a matter of debate, and more comedication-potentially leading to drug-drug interactions and hepatotoxicity-will be necessary in this aging and multimorbid population. Therefore, ongoing monitoring of liver-related mortality and its contributors in HIV-positive persons will remain important. St. Pierre Brussels, Belgium
